COVID-19: Bharat Biotech receives DCGI approval for India’s first intranasal vaccine



The Drugs Controller General of India (DCGI) granted Bharat Biotech emergency use authorization for the Intranasal Covid-19 vaccine on September 6. This will be India’s first nasal vaccine for COVID-19.

Mansukh Mandaviya, Union Minister of Health and Family Welfare, described it as a “significant boost” to India’s fight against Covid-19.

He took to Twitter and said, “Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.”

“This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji’s leadership,” he added.

He also said that we will defeat Covid-19 with a science-driven approach.

“With the science-driven approach and Sabka Prayas, we will defeat COVID-19,” he said.

Avatar photo

Dr. Kirti Sisodhia

Content Writer

ALSO READ

Leave a Reply

Your email address will not be published. Required fields are marked *